-
公开(公告)号：US20240272177A1
公开(公告)日：2024-08-15
申请号：US18561621
申请日：2022-05-16
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Manuel Dietrich , Felix Gruenewald , Martin Hund , Peter Kastner , Martin Klammer , Ruediger Laubender , Heike Wegmeyer , Ursula-Henrike Wienhues-Thelen
IPC: G01N33/68 , G01N33/536 , G01N33/58 , G16H50/30
CPC classification number: G01N33/6893 , G01N33/536 , G01N33/58 , G01N33/6854 , G16H50/30 , G01N2333/4703 , G01N2800/361 , G01N2800/52
Abstract: The present invention relates to methods of assessing whether a patient has adenomyosis or is at risk of developing adenomyosis, to methods of selecting a patient for therapy of adenomyosis, and methods of monitoring a patient suffering from adenomyosis or being treated for adenomyosis, by determining the amount or concentration of sFRP4 in a sample of the patient, and comparing the determined amount or concentration to a reference.
-
公开(公告)号：US20230095167A1
公开(公告)日：2023-03-30
申请号：US17801469
申请日：2021-02-19
Applicant: Universiteit Maastricht , Academisch Ziekenhuis Maastricht , Roche Diagnostics Operations, Inc.
Inventor： Alfred Engel , Michael Gerg , Ute Jucknischke , Johann Karl , Peter Kastner , Thomas Meier , Lars Hillringhaus , Ulrich Schotten , Vinzent Rolny , Ursula-Henrike Wienhues-Thelen , André Ziegler , Roberto Latini , Jennifer Marie Theresia Anna Meessen
Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of BMP10 in a sample from the subject, and comparing the amount of BMP10 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure based on the determination of BMP 10 in a sample from a subject. Further, the present invention relates to a method for predicting the risk of a subject of hospitalization due to heart failure based on the determination of a BMP10-type peptide in a sample from a subject. The present invention further pertains to antibodies which bind to one or more BMP10-type peptides such as NT-proBMP10.
-
3.发明授权公开(公告)号：US11644472B2
公开(公告)日：2023-05-09
申请号：US16217612
申请日：2018-12-12
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Herbert Andres , Dirk Block , Johann Karl , Peter Kastner , Ursula-Henrike Wienhues-Thelen , Roberto Latini , Serge Masson , Andre Ziegler , Edelgard Kaiser , Stefan Palme , Markus Thomas , Simona Barlera
CPC classification number: G01N33/6887 , G01N33/6893 , G01N2800/326
Abstract: A method for predicting the risk of recurrence of Atrial Fibrillation in a subject based on measuring the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject is described. Also described is a method of diagnosing Atrial Fibrillation in a subject suspected to suffer from Atrial Fibrillation based on measuring the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. Also described are devices adapted to carry out the method of the present disclosure.
-
公开(公告)号：US20210215716A1
公开(公告)日：2021-07-15
申请号：US17181386
申请日：2021-02-22
Applicant: Roche Diagnostics Operations, Inc. , Universiteit Maastricht , Academisch Ziekenhuis Maastricht
Inventor： Peter Kastner , Manuel Dietrich , André Ziegler , Ursula-Henrike Wienhues-Thelen , Vinzent Rolny , Ulrich Schotten
Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of SPON-1 in a sample from the subject, and comparing the amount of SPON-1 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to methods for the prediction of stroke based on the amount of SPON-1.
-
公开(公告)号：US20210190801A1
公开(公告)日：2021-06-24
申请号：US17177673
申请日：2021-02-17
Applicant: ROCHE DIAGNOSTICS OPERATIONS, INC. , UNIVERSITEIT MAASTRICHT , ACADEMISCH ZIEKENHUIS MAASTRICT
Inventor： Johann Karl , Peter Kastner , Ursula-Henrike Wienhues-Thelen , Manuel Dietrich , Andre Ziegler , Ulrich Schotten
IPC: G01N33/68 , G01N33/577
Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of BMP 10 in a sample from the subject, and comparing the amount of BMP 10 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure based on the determination of BMP 10 in a sample from a subject. Further, the present invention relates to a method for predicting the risk of a subject of hospitalization due to heart failure based on the determination of a BMP 10-type peptide in a sample from a subject.
-
Patent Agency Ranking
公开(公告)号：US20230341419A1
公开(公告)日：2023-10-26
申请号：US18021047
申请日：2021-08-12
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Vinzent Rolny , Ursula-Henrike Wienhues-Thelen , Andre Ziegler , David Conen , Stefan Osswald , Michael Kuehne , Peter Kastner
IPC: G01N33/68
CPC classification number: G01N33/6896 , G01N2800/2871 , G01N2800/52 , G01N2800/50
Abstract: The present invention relates to a method for assessing whether a subject has experienced one or more silent infarcts in a subject, said method comprising a) determining the amount of the biomarker ESM-1 in a sample from the subject, b) comparing the amount determined in step a) to a reference, and c) assessing whether a subject has experienced one or more silent infarcts. The present invention further relates to a method for predicting silent infarcts and/or cognitive decline, and methods for assessing and monitoring of the extent of silent small and large noncortical and cortical infarcts in a subject. Further encompassed by the present invention are the corresponding uses.
-
公开(公告)号：US20230176077A1
公开(公告)日：2023-06-08
申请号：US17912776
申请日：2021-03-18
Applicant: Universiteit Maastricht , Academisch Ziekenhuis Maastricht , Roche Diagnostics Operations, Inc.
Inventor： Peter Kastner , Vinzent Rolny , Ursula-Henrike Wienhues-Thelen , André Ziegler , Manuel Dietrich , Ulrich Schotten
IPC: G01N33/68
CPC classification number: G01N33/6896 , G01N2800/2871 , G01N2800/326 , G01N2800/50 , G01N2333/9121
Abstract: The present invention relates to a method for aiding in the prediction of stroke and/or dementia in a subject, said method comprising a) determining the amount of the biomarker RET (Rearranged during transfection) in a sample from the subject, b) comparing the amount determined in step a) to a reference, and c) aiding in the prediction of stroke and/or dementia. The present invention further relates to a method for aiding in the assessment of the extent of white matter lesions in a subject, a method for aiding in the assessment whether a subject has experienced one or more silent strokes and to a method for aiding in the diagnosis of atrial fibrillation in a subject. Further encompassed by the present invention are the corresponding uses.
-
公开(公告)号：US20210156875A1
公开(公告)日：2021-05-27
申请号：US17161998
申请日：2021-01-29
Applicant: Roche Diagnostics Operations, Inc. , Universitaet Maastricht , Academisch Ziekenhuis Maastricht
Inventor： Johann Karl , Peter Kastner , Roberto Latini , Vinzent Rolny , Ursula-Henrike Wienhues-Thelen , Andre Ziegler , Manuel Dietrich , Jennifer Meessen , Ulrich Schotten
IPC: G01N33/68
Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of DKK3 in a sample from the subject, and comparing the amount of DKK3 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure and/or at least one structural or functional abnormality of the heart associated with heart failure.
-
公开(公告)号：US20180231570A1
公开(公告)日：2018-08-16
申请号：US15943104
申请日：2018-04-02
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Andrea Horsch , Birgit Klapperich , Dirk Block , Alfred Engel , Johann Karl , Rosemarie Kientsch-Engel , Ekaterina Manuilova , Christina Rabe , Sandra Rutz , Monika Soukupova , Ursula-Henrike Wienhues-Thelen , Peter Kastner , Edelgard Anna Kaiser
IPC: G01N33/68
CPC classification number: G01N33/6893 , G01N33/68 , G01N33/74 , G01N2333/47 , G01N2333/8139 , G01N2800/347 , G01N2800/50
Abstract: The present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) during or after a surgical procedure or after administration of a contrast medium. The method is based on the determination of the level of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) in a body fluid sample obtained from the patient prior to the surgical procedure or prior to the administration of a contrast medium. Further, the present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) based on the determination of the amount of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) and Cystatin C in a body fluid sample obtained from the patient. The present disclosure further encompasses kits and devices adapted to carry out the methods of the disclosed methods.
-
公开(公告)号：US11946938B2
公开(公告)日：2024-04-02
申请号：US16899629
申请日：2020-06-12
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Ursula-Henrike Wienhues-Thelen , Johann Karl , Peter Kastner , Vinzent Rolny , Andre Ziegler , David Conen
CPC classification number: G01N33/6893 , G01N2333/4745 , G01N2333/515 , G01N2800/326 , G01N2800/50
Abstract: The present disclosure demonstrates a method for predicting the risk of stroke of a subject and a method for improving the prediction accuracy of a clinical stroke risk score. The methods are based on the determination of the amount of Angiopoietin-2 (Ang-2) and/or the amount of Insulin-like growth factor-binding protein 7 (IGFBP7) in a sample from a subject. Moreover, disclose is the use of i) the biomarker Ang-2 and/or the biomarker IGFBP7, and/or ii) at least one detection agent that specifically binds to Ang-2 and/or at least one detection agent that specifically binds to IGFBP7 in a sample from a subject for predicting the risk of stroke of said subject.
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.03 seconds)
